Musely turns to alternative financing instead of a traditional venture round
Musely, a direct-to-consumer telemedicine company focused on compounded treatments for skin, hair, and menopause care, has secured more than $360 million in non-dilutive capital from General Catalyst’s Customer Value Fund, according to TechCrunch. The deal stands out in a startup market still dominated by either equity fundraising or conventional debt, because Musely says this structure gives it access to major growth capital without giving up ownership or taking on a standard interest-bearing loan.
The company’s chief executive and co-founder, Jack Jia, told TechCrunch he had not been actively seeking outside financing. Musely, founded in 2014 as a wellness community before pivoting in 2019 to prescription skincare, had already been cash-flow positive for years, he said. That financial position appears to have given the company leverage to reject more conventional venture offers that would have diluted founder ownership.
Instead, Musely chose a structure tied to General Catalyst’s Customer Value Fund, or CVF, which is designed for companies with predictable revenue streams. Rather than taking equity, the fund provides growth capital that is repaid through a fixed, capped share of revenue generated from the funded growth efforts. Jia described the arrangement as mathematically more compelling than a bank loan and less expensive than a dilutive fundraising round.
Why the structure matters
The financing reflects a broader shift in how some later-stage growth companies are approaching expansion. For venture-backed startups, the standard playbook has long centered on raising increasingly large equity rounds to fund customer acquisition, market expansion, and hiring. But that path can be expensive for founders and early investors when valuations are under pressure or when the business already generates meaningful cash flow.
Musely’s case highlights an alternative model better suited to businesses that already know how to acquire customers and monetize them. If revenue is stable enough to forecast, non-dilutive growth funding can become a way to scale without resetting the cap table. That is especially relevant in direct-to-consumer health businesses, where customer acquisition costs can be high and sustained marketing investment is often necessary to maintain growth.
Jia framed the problem in practical terms: once a company reaches significant scale, it can require enormous new capital simply to keep climbing. For brands built around digital customer acquisition, profitable growth is often constrained less by product demand than by the cost of attracting additional customers at scale.
